- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
RadNet buys nine centers, sells one
FDA clears Ziehm mobile C-arm
RadNet buys nine centers, sells one
No sooner had RadNet completed its two-month-old deal to acquire nine New Jersey imaging centers than the company began whittling down the purchase price, turning new assets into hard cash. RadNet sold off a single-modality open MRI center in southern New Jersey, along with some legacy image management systems, for $650,000, thus retrieving a chunk of the $2.1 million paid to Medical Resources for the nine facilities. Tristate Imaging bought the center, which RadNet described as being outside the market served by the closest RadNet centers. The acquisition price will drop further if RadNet sells, as planned, a building in Union, NJ, that it acquired in the deal. The Medical Resources acquisition is part of a strategy to connect RadNet's Mid-Atlantic and southern New York operations. These complement core operations in California, Maryland, and Delaware. All told, RadNet operates a network of 175 fully owned and operated outpatient imaging centers.
FDA clears Ziehm mobile C-arm
The FDA has cleared the Vision RFD, a mobile C-arm from Ziehm Imaging. The compact system is designed for use in endovascular surgery, interventional cardiology, and interventional radiology. It features a flat-panel sensor as part of its digital imaging chain. A large C-arm opening and 165º orbital rotation allow easy patient access.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
